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Theprevalenceandgeneticsusceptibilityofautoimmunediseases(ADs)mayvarydependingonlatitudinalgradientandethnicity.
The aims of this study were to identify common human leukocyte antigen (HLA) class II alleles that contribute to susceptibility to
six ADs in Latin Americans through a meta-analysis and to review additional clinical, immunological, and genetic characteristics
of those ADs sharing HLA alleles. DRB1∗03:01 (OR: 4.04; 95%CI: 1.41–11.53) was found to be a risk factor for systemic lupus
erythematosus (SLE), Sj¨ ogren’s syndrome (SS), and type 1 diabetes mellitus (T1D). DRB1∗04:05 (OR: 4.64; 95%CI: 2.14–10.05)
inﬂuences autoimmune hepatitis (AIH), rheumatoid arthritis (RA), and T1D; DRB1∗04:01 (OR: 3.86; 95%CI: 2.32–6.42) is a
susceptibility factor for RA and T1D. Opposite associations were found between multiple sclerosis (MS) and T1D. DQB1∗06:02
and DRB1∗15 alleles were risk factors for MS but protective factors for T1D. Likewise, DQB1∗06:03 allele was a risk factor for
AIH but a protective one for T1D. Several common autoantibodies and clinical associations as well as additional shared genes have
been reported in these ADs, which are reviewed herein. These results indicate that in Latin Americans ADs share major loci and
immune characteristics.
1.Introduction
Autoimmune diseases (ADs) are chronic conditions initiated
by the loss of immunological tolerance to self-antigens.
They are a heterogeneous group of disorders that aﬀect
speciﬁc target organs or multiple organ systems [1]. Almost
all ADs disproportionately aﬀect middle-aged women and
are among the leading causes of death for this group
of patients [2]. The etiology of ADs is unknown, but
these complex diseases are known to feature genetic and
environmental factors in their development [1, 3]. Although
they exhibit contrasting epidemiological features and clinical
manifestations, there is evidence that ADs share similar
immunogenetic mechanisms [4].
Three related lines of evidence sustain the common
origin for ADs. First, clinical evidence highlights the co-
occurrence of distinct ADs within an individual (i.e., polyau-
toimmunity) and within members of a nuclear family (i.e.,
familial autoimmunity). Second, physiopathologic evidence
indicates that the pathologic mechanisms may be similar
amongADs.Third,geneticevidenceshowsthatautoimmune
phenotypes might represent pleiotropic outcomes of the
interaction of nonspeciﬁc disease genes [5].
The study of HLA, which carries the major genetic in-
ﬂuence on susceptibility to ADs, will allow us to understand
its common or speciﬁc inﬂuence on these diseases and to
identify genetic prediction markers. The large and diverse
population of Latin America (LA) is a powerful resource
for elucidating the genetic basis of complex traits due to its
admixture [6]. Modern day LA resulted from the encounter
of Europeans with the indigenous people of the Americas
in 1492, followed by waves of migration from Europe and
Africa. Asa result,the genomicstructureofpresent day Latin
Americans is determined by both the genetic structure of
the founding populations and the numbers of migrants from2 Autoimmune Diseases
these diﬀerent populations [7]. Analysis of multiple Latino
populations in gene association studies could also strengthen
the potential associations as well as provide opportunities
for examining gene-environment and gene-gene interactions
[8].
The purpose of this paper was to estimate the common
eﬀect size of HLA class II on ADs across LA populations
through a meta-analysis and to evaluate the additional
characteristics (i.e., other genes, autoantibodies, and clinical
characteristics) of genetically associated ADs in Latin Ame-
rica.
2.MaterialsandMethods
2.1. Study Selection. Five meta-analyses of HLA class II
polymorphisms in LA patients with ADs published from
2007 to 2010 by our group were included [9–13]. The ADs
included were rheumatoid arthritis (RA), systemic lupus
erythematosus(SLE),autoimmunehepatitis(AIH),multiple
sclerosis (MS), and type 1 diabetes (T1D). In addition,
the results from the only study of Sj¨ o g r e n ’ ss y n d r o m e( S S )
reported on the LA population were included [14]. Brieﬂy,
the strategies to search for, select, and analyze the studies
used for each meta-analysis are mentioned hereinafter.
In all of the cases, a systematic review of the elec-
tronic databases (MEDLINE, PubMed, SciELO, BIREME,
EMBASE, Cochrane, and LILACS) was done independently
by two experts. The searches only included publications
on HLA-Class II alleles and susceptibility to ADs in LA
published in any of these three languages: Spanish, English,
or Portuguese. All of the search strategies included MeSH
terms: “HLA DR/DQ antigens” and “Major Histocompa-
tibily Complex”. However, other major topics were used
depending on the speciﬁc AD: “Arthritis, Rheumatoid”,
“Lupus Erythematosus, Systemic”, “Hepatitis, Autoimmune”,
“Hepatitis, Chronic”, “Multiple Sclerosis”, “Type 1 Diabetes”,
or “Autoimmune Diabetes”.
The inclusion criteria were the following: (1) AD di-
agnosis established using international validated crite-
ria for RA [15], for SLE [16], for AIH [17, 18], for
MS [19, 20], and for T1D [21, 22]; (2) case-control
design of the study; (3) publication of suﬃcient infor-
mation to calculate odds ratios (ORs); (4) a focus on a
well-deﬁned LA population; (5) use of molecular tech-
niques to determine HLA polymorphisms (i.e., allele-
speciﬁc oligonucleotides—ASO, polymerase chain reaction
with sequence-speciﬁc primers—PCR/SSP, restriction frag-
ment length polymorphism—RFLP, speciﬁc oligonucleotide
probes—SOP, or sequence-speciﬁc oligonucleotide probes—
SSOP); and (6) manuscript’s publication in a peer-reviewed
j o u r n a la saf u l lp a p e r .S u m m a r i e so ra b s t r a c t sw e r en o t
accepted.
Data were analyzed using the Comprehensive Meta-
Analysis version 2 program (Biostat, Englewood, NJ, 2004).
For each polymorphism group, the eﬀect summary odds
ratio (OR) and 95% conﬁdence interval (CI) were obtained
bytherandomeﬀectmodel.Thesystematicreviewandmeta-
analysis were done following the PRISMA guidelines and the
respective checklist completion [23].
2.2. Meta-Analysis. Calculations were carried out for each
HLA-DR and HLA-DQ allele using low or high resolution
based on information available in each meta-analysis. The
ﬁnal pooled OR was done by weighing individual OR by the
inverse of their variance. For each allele, the ﬁnal eﬀect OR
and 95%CI were obtained by means of a random model.
This model was used because of the assumption that there
is a distribution of true eﬀect sizes rather than one true
eﬀect, assigning a more balanced weight to each study.
It was also used because all the studies were considered
to be functionally unequal. Values less than 1.0 suggest a
protective eﬀect while values greater than 1.0 suggest a risk
for each AD. Heterogeneity was calculated by means of
Cochran’s (Q) and Higgins’s (I2) tests. The I2 test measures
the degree of inconsistency in the studies by calculating
the percentage of total variation across studies due to
heterogeneityratherthanchanceandwasexpressedasaratio
with a range of 0% to 100%. A qualitative classiﬁcation of
low, moderate, and high were assigned to I2 values of 25%,
50%, and 75%, respectively. A signiﬁcant Q-statistic (P<
0.10) indicated heterogeneity across studies. Publication
bias was determined using Funnel plots, Egger’s regression
asymmetry tests, and sensitivity analysis. Data were analyzed
by using Comprehensive Meta-Analysis version 2 program.
2.3. Literature Review. An updated systematic literature
review was done following the PRISMA guidelines [23]f o r
the prevalence of autoantibodies in RA, SLE, AIH, T1D, SS,
and MS (Figure 1). Publications were identiﬁed through a
systematic search done in Pubmed. The inclusion criteria
were the following: (1) studies in humans, (2) restricted by
title, (3) articles published in the last 20 years, (4) the sample
size must be higher than 100 patients for SLE and RA studies
and higher than 50 patients for SS, AIH, T1D, and MS stu-
dies,and(5)enoughdataavailabletocalculatetheprevalence
of the antibodies in each AD. All of the search strategies
included MeSH terms: “diabetes mellitus, type 1”, “lupus
erythematosus, systemic”, “arthritis, rheumatoid”, “Sj¨ ogren’s
syndrome”, “hepatitis autoimmune”, and “multiple sclerosis”.
In addition, key words for searching 20 antibodies were used
including ANAs: antinuclear antibodies (ANAs), antidouble
stranded DNA antibodies (Anti-dsDNA), antiribonucleo-
proteinantibodies (Anti-RNP),anti-Smith antibodies (Anti-
Sm), Anti-Ro, Anti-La, lupic anticoagulant (LAC), IgG anti-
cardiolipins, IgM anticardiolipins, anti-beta-2-glicoprotein
I( A n t i - β2GPI), rheumatoid factor (RF), anti-cyclic citrul-
linated peptide (Anti-CCP) antibodies, antiglutamic acid
decarboxylase (Anti-GAD) antibodies, anti-islet cell anti-
bodies (ICAs), anti-insulin antibodies (IAAs), antimito-
chondrial antibodies (AMAs), antismooth muscle antibod-
ies (ASMAs), antithyroglobulin (Anti-TG) antibodies, and
antithyroidperoxidase(Anti-TPO)antibodies.Thecomplete
search is described in detail in Table 1 in Supplementary
Material available online at doi:10.1155/2012/569728.
3. Results
3.1. Meta-Analysis for Association between HLA-II Alleles
and ADs. A total of ﬁve meta-analysis of HLA class IIAutoimmune Diseases 3
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Figure 1: Flow chart of the systematic literature review.
polymorphisms in LA patients with ADs (RA, SLE, AIH, MS,
and T1D) and the unique report for SS in LA were evaluated
(Figure 2).
A total of 3727 cases and 8465 controls were analyzed,
and diﬀerent types of association between alleles and ADs
were found (Table 1). These included three risk alleles for
two or more ADs, four opposite associations (the same allele
is a risk factor for one AD, but a protective factor for other
AD), thirteen risk alleles for a particular AD, and eight
protective alleles that are disease-speciﬁc. The associations
were grouped through network in Figure 3.
There are two risk alleles associated with three ADs. The
ﬁrst is DRB1∗03:01 that was found to be a risk for SLE, SS,
andT1DwhilethesecondisDRB1∗04:05thatwasassociated
with AIH, T1D, and RA. Similarly, there is one risk allele
associated with two ADs. It is DRB1∗04:01 which was found
to impart risk for RA and T1D.
Interestingly, two opposite associations were found
between MS and T1D. DQB1∗06:02 and DRB1∗15 alleles
were risk factors for MS but protective factors for T1D.
Likewise, an opposite association was found between AIH
and T1D in that DQB1∗06:03 was a risk factor for AIH but
protective factor for T1D.
In addition, thirteen risk disease-speciﬁc alleles were
found. Those are seven for T1D, three for MS, two for RA,
and one for AIH while, conversely, eight protective alleles for
ap a r t i c u l a rA Dw e r er e p o r t e d .T h o s ea r eﬁ v ef o rT 1 D ,t w o
for AIH, and one for SLE (Table 1).
3.2.StudyQuality. Signiﬁcantheterogeneitywasnotseenfor
theDRB1∗04:01allele(I2 = 0%;Q = 0;P = 0.98).Moderate
heterogeneity for the DRB1∗04:05 allele was observed (I2 =
57%; Q = 4.65; P = 0.098). High heterogeneity was found
by meta-analysis for the DRB1∗03:01 allele (I2 = 87.93%;
Q = 16.57; P<0.001). There was no evidence of publication
biasinthecurrentmeta-analysisaccordingtotheFunnelplot
and Egger’s regression test (data not shown).
3.3. Sharing of Autoantibodies in ADs. Findings are summa-
rizedinSupplementaryTable 2.PresenceofANAswasfound
inalloftheanalyzedADs.Theseautoantibodies,asexpected,
were more prevalent in SLE (even over 75%) than other
ADs. However, prevalence of ANAs over 60% was observed
in SS, RA, and AIH. Anti-dsDNA, Anti-RNP and Anti-Sm
antibodies were observed in SLE, RA, and SS. Anti-Ro and
Anti-La antibodies were presented mainly in SS over 50%.
Also, these two antibodies were presented in SLE, RA and
AIH. In our revision, LAC was only present in SLE patients,
but not in other ADs. IgG anticardiolipins were found in all
ADs with diﬀerent prevalences, SLE being the most frequent
one. Otherwise, IgM anticardiolipins were presented in all
ADs, but they were less prevalent than IgG subtype. Anti-
β2GPI antibodies (IgG and IgM subtypes) were observed
mainly in SLE, but they were present in all diseases, except in
SS. RF was present in other ADs diﬀerent to RA, such as SLE,
SS, MS, and AIH. Likewise Anti-CCP antibodies were found
in all ADs except in MS, although the prevalence was lower
than28%.SharedautoantibodiesinADsalsowereAnti-TPO
and Anti-TG (present in all ADs except in AIH). Conversely,
Anti-GAD, ICA, and IAA were observed only in T1D and
AIH.
The prevalence of autoantibodies varied widely due to
laboratorytechniques,population,typeofstudy,andactivity
of AD.4 Autoimmune Diseases
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Figure 2: Previous results obtained from ﬁve meta-analyses and one original article.Autoimmune Diseases 5
Table 1: Associations between HLA class II and six ADs: SLE, RA, T1D, AIH, SS, and MS.
Association Allele AD OR Lower
limit
Upper
limit P valuea
Risk (for only one
AD)
DQA1∗03:01 T1D 2.65 1.23 5.72 0.013
DQA1∗05:01 T1D 2.43 1.34 4.38 0.003
DQB1∗02:01 T1D 2.97 2.05 4.30 <0.001
DQB1∗03:02 T1D 4.45 3.29 6.02 <0.001
DRB1∗03 T1D 2.69 1.41 5.15 0.003
DRB1∗04 T1D 3.83 2.02 7.27 <0.001
DRB1∗04:02 T1D 3.23 1.63 6.39 0.001
DQB1∗06 MS 2.18 1.55 3.08 <0.001
DRB1∗15:01 MS 2.59 1.68 4.02 <0.001
DRB1∗15:03 MS 2.24 1.39 3.62 0.001
DRB1∗01:01 RA 1.71 1.23 2.39 0.002
DRB1∗04:04 RA 3.42 1.54 7.63 0.003
DRB1∗13:01 AIH 4.84 2.83 8.26 <0.001
Risk (for more
than one AD)
DRB1∗04:01 T1D and RA 3.86 2.32 6.42 <0.001
DRB1∗03:01 SLE, SS and T1D 3.56 1.42 11.54 0.009
DRB1∗04:05 AIH, T1D and RA 4.64 2.14 10.05 <0.001
Protection (for
only one AD)
DQB1∗05 T1D 0.31 0.19 0.51 <0.001
DQB1∗05:01 T1D 0.41 0.24 0.68 <0.001
DRB1∗11 T1D 0.27 0.17 0.42 <0.001
DRB1∗13 T1D 0.37 0.24 0.58 <0.001
DRB1∗14 T1D 0.18 0.06 0.55 0.002
DQB1∗03:01 AIH 0.33 0.19 0.56 <0.001
DRB1∗13:02 AIH 0.16 0.05 0.45 0.001
DRB1∗11:01 SLE 0.21 0.006 0.72 <0.001
Opposite
associations
DQB1∗06:02 MS risk 2.49 1.67 3.71 <0.001
T1D protection 0.17 0.09 0.29 <0.001
DQB1∗06:03 AIH risk 4.48 1.28 15.73 <0.001
T1D protection 0.29 0.18 0.87 <0.001
DRB1∗15 MS risk 2.28 1.69 3.07 <0.001
T1D protection 0.38 0.22 0.65 <0.001
aα = 0.05.
Each OR and its CI show the eﬀect size and precision for individual studies and for the combined eﬀect calculated by the random model.
AD: autoimmune disease; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; AIH: autoimmune hepatitis; T1D: type 1 diabetes; SS: Sj¨ ogren’s
syndrome; MS: multiple sclerosis; OR: odds ratio.
4. Discussion
In this meta-analysis, the genetic commonality in ADs was
analyzed by examining the contributions from HLA-II alleles
which confer associated risk or protection to six ADs: RA,
SLE, AIH, MS, SS, and T1D in the LA population [9–14].
Two types of genetic risk factors were found: those common
to many diseases and those speciﬁc to a given disorder. In
addition, opposite associations between two diﬀerent ADs
and the same allele were found.
The LA population is a mixed group with ancestries that
include blacks, Caucasians, and Amerindians, which reﬂects
a notable racial, genetic, and cultural diversity [8]. However,
our results showed that the eﬀect of HLA-class II alleles
on ADs in LA is similar to the reported eﬀect on other
populationsregardlessoflatitudinalgradientandadmixture.
For instance, DRB1∗03:01, DRB1∗04:05, DRB1∗04:01, and
DQB1∗02:01 risk alleles for T1D in LA also confer suscep-
tibility in Caucasians and Asians [13]. DRB1∗03:01 allele,
which has been described in the Colombian population to
be a risk factor for SS, was also associated with the disease at
theworldwidelevel[54].Furthermore,somenon-HLAgenes
that inﬂuence the risk of developing ADs in Caucasians also
have the same eﬀect in Latin Americans (i.e., C8orf13-BLK
and CD226 genes) [55]. In contrast, some non-HLA genes
inﬂuencing the developing ADs in a particular population
are not replicated in another one (i.e., PADI4 and SLC22A4
genes) [56].
Several studies have indicated that the major histo-
compatibility complex (MHC) is one of the central loci6 Autoimmune Diseases
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Figure 3: The complex interplay of HLA in six autoimmune diseases in Latin Americans.
contributing to the development of ADs [25, 57]. Our results
show that three alleles identiﬁed in previous analyses [9–14]
of a particular disease were found to inﬂuence the risk of
at least two diseases. The DRB1∗03:01 allele was found to
be a risk for SLE, SS, and T1D while DRB1∗04:05 allele was
associated with AIH, T1D, and RA. In addition, DRB1∗04:01
allele confers susceptibility to T1D and RA. Analyses of
other polymorphic genes related to autoimmune response
and inﬂammation have been carried out. Results indicated
that PTPN22 1858T/C [25]a n dTNF-α-308G/A [31, 58, 59]
alleles are associated with SLE, SS, and T1D. Likewise, the
CTLA4 gene has been reported as a risk factor for AIH,
T1D, and RA [37, 60, 61]. Other non-HLA genes that impart
risk to develop two or more ADs in LA population have
been also identiﬁed. For instance, ITGAM and its variant
(rs1143679, Arg77His) are associated with SLE and systemic
sclerosis (SSc) [62]. Another example is the association of
rs6822844 in the IL2-IL21 region with SLE, T1D, and SS in
non-European populations [24].
Our results demonstrated that there are both common
susceptibility and protective alleles for ADs and single
alleles involved in the development of ADs (Table 1). The
DRB1∗04:04 allele, which speciﬁcally inﬂuences susceptibi-
litytoacquireRA,wasidentiﬁed.Ithasaconservedmotif(L-
LE-[Q/R]-[R/K]-R-A-A) comprising residues 67–74 in the
third hypervariable region of the DRβ1 chain, known as the
shared epitope (SE). These residues constitute an α-helical
domain which forms one side of the antigen binding site, a
site likely to aﬀect antigen presentation [63]. Thus, the SE
might selectively bind an arthritogenic peptide which could
favor an autoimmune response. LA individuals carrying
SE alleles have 3.5-fold higher risk of developing RA than
noncarriers [9].
Although we identiﬁed common HLA class II alleles
that contribute to susceptibility to diﬀerent ADs, there is
evidence indicating that two clinically distinct ADs with
diﬀerent susceptibility HLA-II alleles share other common
genetics variants. Using a very large sample set, Zhernakova
et al. compared the genetic basis of RA and celiac disease
(CD). They found 14 loci that contribute to the risk of
both diseases including CD247, UBE2L3, DDX6, UBASH3A,
SH2B3, 8q24.2, STAT4,a n dTRAF1-C5.H o w e v e r ,i ti s
known that RA and CD have diﬀerent HLA risk alleles
(HLA-DQ∗A1 and DQ∗B1 alleles in CD and HLA-DRB1Autoimmune Diseases 7
Table 2: Relationship between genetic and clinical features with HLA-ADs associations.
Associations Genetic associations (ref) Clinical association (ref)
SLE, SS, T1D Shared risk genes Common clinical characteristics
(i) IL2–IL21 (rs6822844) [24]
(ii) PTPN22 (1858T/C) [25, 26]
(i) Human endogenous retroviruses (HERVs)
are associated with multiple ADs including
SLE, SS, and T1D [27]
(ii) Coexistence of SLE and SS has been
reported [28, 29]
(iii) 8.1 Ancestral Haplotype [30]
(iv) TNF-α (-308G/A) [31–33]
AIH, RA, T1D Shared risk genes
(i) DRB1∗04:05 [34–36]
(ii) CTLA4 [37–39]
(iii) Hepatitis C virus has been related to ADs such as RA,
AIH, T1D, SLE, SS, and others [40]
(iv) AIH was found in 0% to 1.7% of patients with SS.
However, the prevalence of abnormal liver function test in SS
patients is close to 47% [41]
(v) High prevalence of ADs in siblings of probands aﬀected
by AITD, MS, RA, T1D, SLE, and others ADs [42]
MS, T1D Shared risk genes Common clinical characteristics
(i) CD226 (rs763361), CLEC16A (rs12708716),
SH2B3 (rs3184504) [43, 44]
(ii) ZSCAN23 (rs11752919) [45]
(i) A latitudinal gradient characterizes both diseases. MS and
T1D each become increasingly common as distance from the
Equator increases [43]
(iii) KIF5A (rs1678542), SH2B3 (rs3184504),
CD226 (rs763361) [46]
(ii) Protective eﬀect of vitamin D levels [43]
(iii) Association to Epstein-Barr virus infection
[43]
(iv) Both MS and T1D are characterized by T
cell-mediated autoimmunity. The targets of T
cells are pancreatic islet and central nervous
system antigens in both diseases [43]
(v) Familial aggregation [47, 48]
Shared protective genes:
(i) HLA-DRB1∗01, HLA-DRB1∗10,
HLA-DRB1∗11, and HLA-DRB1∗14 [43]
Opposite gene associations:
(i) Risk for T1D but protection for MS [45]: TAP2
(rs10484565), VARS2 (rs1264303), CDSN
(rs1265048), NOTCH4 (rs2071286), BTNL2
(rs2076530), TRIM40 (RS757262)
(ii) Risk for MS but protection for T1D [45, 49]:
CDSN (rs3130981), HLA-DMB (rs151719) IL2RA
(rs35285258), IL2RA (rs7090530)
AIH, T1D Shared protective alleles Controversial characteristics
(i) DQB1∗03:01 [11, 50]
Controversial genetic and clinical characteristics:
(ii) In children with AIH, the frequency of
high-risk HLA DQB1∗03:02 or DQB1∗02 alleles
was low and similar to control frequencies,
indicating low risk for DM despite the presence of
DM-related autoimmunity markers [51]
(i) One case report with Grave’s disease, AIH and T1D [52]
(ii) One cohort of 278 patients with AIH presented only two
cases of T1D [53]
(iii) One study reported that the prevalence of ICA and IAA
antibodies in children with AIH was 60.7 and 18.5%
respectively. However, only one patient developed T1D [51]
“SE” alleles in RA). According to the authors’ hypothesis,
the HLA-II molecules in these two ADs confer risk by
preferentially presenting disease-speciﬁc antigens (gluten in
CD, most likely citrullinated antigens in RA) to autoreactive
T cells. Therefore, the disease speciﬁcity is determined in
large part by the inheritance of speciﬁc HLA alleles and
exposure to disease-speciﬁc antigens. The speciﬁc genes
could be inﬂuencing downstream signaling events common
to both diseases that may lead to altered T-cell activation and
diﬀerentiation [64].
With regard to opposite associations DQB1∗06:02 and
DRB1∗15 alleles were found to be risk factors for MS but
protective factors for T1D. Our results are similar to those
from other studies reporting that other MHC genes such
as CDSN and HLA-DMB (rs3130981-A and rs151719-G,
resp.) are risk factors for MS, but protective ones for T1D
[45]. However, there is also evidence of the inverse relation.
For instance, TAP2 (rs10484565-T), VARS2 (rs1264303-
G), NOTCH4 (rs2071286-A), BTNL2 (rs2076530-G), and
TRIM40 (rs757262-T) were found to be risk factors for T1D
but protective factors for MS [45]. Despite the presence of
these genetically opposite associations, it is important to
mention that clinical evidence supporting the coexistence
of MS and T1D has been reported [65, 66]. Thus, these
pleiotropic eﬀects can be explained by the combined action
of diﬀerent alleles of several genes and environmental factors
that change the biological context of the SNPs in diﬀerent
individuals and populations (Table 2).
Shared autoantibodies in ADs are described also. ANAs
were presented in multiple ADs such as SLE, SS, RA, T1D,8 Autoimmune Diseases
AIH, and MS. These autoantibodies are not speciﬁc for one
AD. Furthermore, no autoantibody that was exclusive to a
single AD was found. The theory that ADs have a common
origin and similar pathogenic mechanisms receives support
from these ﬁndings (Supplementary Table 2). These sero-
logical results reinforce the genetic ﬁndings of the present
meta-analysis. In addition, there are pathophysiological
mechanisms and clinical features supporting our ﬁndings
(Table 2). There is evidence that an AD can be induced or
triggered by infectious agents (i.e., viruses or bacteria) via
diﬀerent mechanisms, such as an alteration of expression of
some genes involved in immune regulation, the induction
of foreign proteins that could trigger the production of
autoantibodies in B cells, and molecular mimicry [27]. Se-
veral epidemiologic studies have demonstrated that human
endogenous retroviruses (HERVs), hepatitis C virus (HCV)
[40], and Epstein-Barr virus (EBV) [43] are associated with
diﬀerent ADs (Table 2). Furthermore, elevated prevalence of
HCV has been reported in ADs and suggests that it plays
a pathogenic role triggering the production of ANAs, RF,
anticardiolipin, and Anti-TG antibodies [40].
Another consideration concerning genetic ﬁndings is the
familial aggregation. Relatives of patients with ADs have
a higher risk for developing the same or other ADs than
general population. These ﬁndings have been reported in
AITD, RA, MS, SLE, and T1D [42, 47, 48].
Regarding the opposite association between AIH and
T1D, there is one study with more than 250 AIH patients
in which only two cases of T1D were presented [53]. Also,
there is a report of one patient with AIH, T1D, and Grave
 s
disease (i.e., multiple autoimmune syndrome) [52]. Finally,
one study in which children with AIH were evaluated for
T1D-related autoantibodies and susceptibility alleles has
been reported. da Silva et al. found a high prevalence of
autoantibodies but despite these ﬁndings, the prevalence of
risk alleles for T1D was similar to controls and only one
patient developed T1D after 3 years [51].
In summary, our results validate the common origin of
ADs paradigm. The ﬁnding of signiﬁcant risk and protective
alleles in LA and the fact that they are shared with other
populations around the world highlights the primary role
of some HLA regions in the genetic susceptibility to ADs
regardless of latitudinal gradient and ethnicity.
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